Chunrong Lin, MD
Pulmonary Disease · Ewa Beach
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Queens University Medical Group · The Queens Medical Center · Queens North Hawaii Community Hospital
Hospitals listed: Pali Momi Medical Center · The Queens Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lin’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A125591 · Current
Licensed to practise in California · since 2013 · expires 2027-05-31 · National University of Singapore Faculty of Medicine].
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Pali Momi Medical CenterAiea, HIAcute Care Hospital · Proprietary · Has an emergency departmentPart of Hawaii Pacific Health, which runs 4 hospitalsPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.166, Oct 2024 – Sep 2025
- The Queens Medical CenterHonolulu, HIAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of The Queens Health Systems, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.34 (1.12 to 1.55), Jul 2022 – Jun 2024Worse than the national rate — Iatrogenic pneumothorax rate: 0.47 (0.29 to 0.65) · 11,638 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.32 (3.74 to 6.9) · 3,569 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.79 (1.36 to 2.23) · 10,444 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.453, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.427, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.345, Oct 2024 – Sep 2025
See every measure and the patient survey for Pali Momi Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.166 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.84 (0 to 1.82) · 823 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.44 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.97 (113.96 to 211.98) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 218 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 415 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 151 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,907 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.12 to 0.54) · 3,322 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 3,332 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.79 (0.59 to 4.99) · 834 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.53 (0 to 3.19) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.61 to 3.75) · 741 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.46 (0 to 13.24) · 243 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.89 (1.03 to 8.74) · 219 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.96 (0.48 to 3.43) · 267 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.42 (0 to 1.16) · 2,957 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.924 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.919 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.312 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 219 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 413 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 15.1 · 144 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 40.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.5 · 422 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 606 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (4.5 to 9.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.5 to 15.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.2 to 16.3) · 578 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.5) · 387 cases | No different | Jan 2024 – Dec 2024 |
What patients said (419 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 59% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for The Queens Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.34 (1.12 to 1.55) | Worse | Jul 2022 – Jun 2024 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.47 (0.29 to 0.65) · 11,638 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.32 (3.74 to 6.9) · 3,569 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.79 (1.36 to 2.23) · 10,444 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.453 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.427 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.345 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.12 to 1.78) · 2,583 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.61 (147.16 to 216.07) · 200 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 619 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 815 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 1,115 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 7,459 cases | None | Jul 2024 – Jun 2025 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.11 to 0.45) · 12,099 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.17 (0 to 2.44) · 1,411 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.9 (1.73 to 4.06) · 3,175 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.07 (2.95 to 11.2) · 1,400 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.22 (1.54 to 6.91) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.45 (0.06 to 2.83) · 821 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 163 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.143 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 501 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 1,438 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.8 · 272 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5 · 698 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.4 · 799 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 1,657 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.1 to 8.6) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (9.1 to 13.9) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 122 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.5 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (10 to 16.1) · 2,546 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 768 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,104 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$34,377
Medicare paid this office $34,377 for 148 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 42 | $11,251 | $161 |
| Critical care, each additional 30 minutes | 27 | $4,514 | $81 |
| Return visit (30+ min) | 33 | $3,895 | $71 |
| Long return visit (40+ min) | 20 | $3,085 | $110 |
| New patient visit (45+ min) | 27 | $2,514 | $93 |
See all 12 services
| Critical care, first 30-74 minutes | 42 | $11,251 | $161 |
| Critical care, each additional 30 minutes | 27 | $4,514 | $81 |
| Return visit (30+ min) | 33 | $3,895 | $71 |
| Long return visit (40+ min) | 20 | $3,085 | $110 |
| New patient visit (45+ min) | 27 | $2,514 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,145 | $89 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $826 | $64 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 15 | $328 | $13 |
| Ultrasonic guidance for blood vessel access | 12 | $147 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 16 | $123 | $8 |
| Test to determine lung volumes using sensors | 13 | $121 | $9 |
| Test to examine how well the lungs exchange gases | 18 | $119 | $7 |
Who their Medicare patients are
148 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 23% · Women 55% · Also on Medicaid 18% · Health risk score 2.83. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 61% · Heart failure 51% · COPD 49% · Coronary heart disease 47% · Diabetes 46% · Atrial fibrillation 39% · Cancer 26% · Dementia 19% · Depression 16% · Stroke 14%.
The office billed $116,317, Medicare allowed $44,387 and paid $34,377; for 427 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 148 | 427 | 76 | 2.83 | $116,317 | $34,377 |
| 2023 | 138 | 330 | 76 | 2.15 | $82,288 | $24,750 |
| 2022 | 111 | 264 | 74 | 2.24 | $84,069 | $25,294 |
| 2021 | 118 | 318 | 75 | 2.29 | $84,098 | $32,118 |
| 2020 | 115 | 277 | 73 | 2.97 | $72,962 | $28,845 |
| 2019 | 111 | 266 | 73 | 2.37 | $66,517 | $24,482 |
| 2018 | 57 | 105 | 73 | 2.18 | $32,801 | $11,547 |
| 2017 | 304 | 703 | 71 | 1.84 | $84,729 | $22,852 |
| 2016 | 150 | 313 | 72 | 1.99 | $40,484 | $8,748 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Critical care, first 30-74 minutes | 48 | $10,133 | $166 |
| Return visit (30+ min) | 34 | $4,527 | $72 |
| Critical care, each additional 30 minutes | 23 | $2,780 | $87 |
| New patient visit (45+ min) | 18 | $1,859 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,760 | $98 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $200 | $8 |
| Test to examine how well the lungs exchange gases | 26 | $188 | $7 |
| Test to determine lung volumes using sensors | 19 | $185 | $10 |
2022: 4 services
| Critical care, first 30-74 minutes | 45 | $11,887 | $170 |
| Return visit (30+ min) | 26 | $3,443 | $75 |
| Critical care, each additional 30 minutes | 24 | $3,352 | $80 |
| New patient visit (45+ min) | 15 | $1,683 | $112 |
2021: 6 services
| Critical care, first 30-74 minutes | 38 | $14,364 | $177 |
| Critical care, each additional 30 minutes | 21 | $5,126 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,934 | $84 |
| New patient visit (45+ min) | 24 | $2,235 | $93 |
| Return visit (30+ min) | 12 | $1,104 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $900 | $60 |
2020: 8 services
| Critical care, first 30-74 minutes | 41 | $10,762 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $3,508 | $88 |
| Critical care, each additional 30 minutes | 18 | $2,783 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,374 | $170 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,972 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,639 | $61 |
| New patient visit (45+ min) | 14 | $1,417 | $101 |
| Return visit (30+ min) | 11 | $1,000 | $62 |
2019: 7 services
| Critical care, first 30-74 minutes | 38 | $10,784 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,019 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,004 | $154 |
| New patient visit (45+ min) | 16 | $1,606 | $100 |
| Critical care, each additional 30 minutes | 15 | $1,562 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,021 | $60 |
| Test to measure expiratory airflow and volume | 17 | $115 | $7 |
2018: 2 services
| Critical care, first 30-74 minutes | 31 | $7,057 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,370 | $81 |
2017: 14 services
| New patient visit (45+ min) | 31 | $3,870 | $125 |
| Return visit (30+ min) | 30 | $3,421 | $70 |
| Return visit (30+ min) | 25 | $2,239 | $59 |
| Long return visit (40+ min) | 14 | $1,611 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,101 | $65 |
| Long return visit (40+ min) | 11 | $897 | $82 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 72 | $875 | $12 |
| Test to examine how well the lungs exchange gases | 90 | $746 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 54 | $624 | $12 |
| Test to determine lung volumes using sensors | 56 | $618 | $11 |
| Test to examine how well the lungs exchange gases | 67 | $553 | $8 |
| Test to determine lung volumes using sensors | 41 | $449 | $11 |
| Test to measure expiratory airflow and volume | 56 | $425 | $8 |
| Test to measure expiratory airflow and volume | 42 | $316 | $8 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $836 | $64 |
| Test to examine how well the lungs exchange gases | 90 | $744 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $494 | $12 |
| Test to measure expiratory airflow and volume | 55 | $425 | $8 |
| Test to determine lung volumes using sensors | 32 | $355 | $11 |
| Test to measure expiratory airflow and volume | 22 | $167 | $8 |
Medicaid work
$7,026 in 2024
Medicaid paid $7,026 for 54 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 23 | $3,674 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 18 | $3,352 |
| Documentation that patient is a current non-tobacco user | 13 | $0 |
| 2024 | 54 | 3 | 16 | $7,026 |
| 2023 | 59 | 1 | 14 | $7,269 |
| 2021 | 54 | 2 | 17 | $7,925 |
| 2019 | 19 | 1 | 12 | $2,173 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 59 | $7,269 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 41 | $6,025 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 13 | $1,901 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 19 | $2,173 |
Drugs they prescribed that Part D paid
$636,586
Pharmacies billed $636,586 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 729) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
277 generic and 452 brand-name prescriptions · $636,586 in drug cost · 62 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Arikayce | 21 | $323,110 | $15,386 |
| Trelegy Ellipta | 161 | $141,045 | $876 |
| Breztri Aerosphere | 63 | $46,511 | $738 |
| Anoro Ellipta | 20 | $11,812 | $591 |
| Incruse Ellipta | 26 | $10,984 | $422 |
See all 17 drugs
| Arikayce | 21 | $323,110 | $15,386 |
| Trelegy Ellipta | 161 | $141,045 | $876 |
| Breztri Aerosphere | 63 | $46,511 | $738 |
| Anoro Ellipta | 20 | $11,812 | $591 |
| Incruse Ellipta | 26 | $10,984 | $422 |
| Combivent Respimat | 16 | $7,770 | $486 |
| Breo Ellipta | 14 | $5,674 | $405 |
| Wixela Inhub | 38 | $3,585 | $94 |
| Albuterol Sulfate Hfa | 104 | $3,360 | $32 |
| Roflumilast | 12 | $1,947 | $162 |
| Azithromycin | 39 | $1,785 | $46 |
| Ventolin Hfa | 21 | $1,659 | $79 |
| Ethambutol | 20 | $1,020 | $51 |
| Montelukast | 41 | $856 | $21 |
| Rifampin | 12 | $648 | $54 |
| Fluticasone Propionate | 11 | $155 | $14 |
| Prednisone | 41 | $116 | $3 |
Year by year
| 2024 | 729 | 93 | 0% (0) | 62% | $636,586 |
| 2023 | 543 | 73 | None | 58% | $404,148 |
| 2022 | 336 | 59 | 0% (0) | 65% | $224,839 |
| 2021 | 179 | 32 | 0% (0) | 69% | $104,605 |
| 2020 | 108 | 20 | 0% (0) | 49% | $25,194 |
| 2019 | 43 | 20 | 0% (0) | 51% | $9,259 |
| 2018 | 51 | 16 | 0% (0) | 51% | $10,621 |
| 2017 | 325 | 62 | 0% (0) | 49% | $57,971 |
| 2016 | 50 | 14 | 0% (0) | 48% | $7,468 |
| 2014 | 36 | None | 0% (0) | 47% | $6,175 |
| 2013 | 321 | 35 | None | None | $28,808 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Arikayce | 14 | $217,807 | $15,558 |
| Trelegy Ellipta | 91 | $76,764 | $844 |
| Anoro Ellipta | 34 | $18,324 | $539 |
| Breztri Aerosphere | 27 | $17,785 | $659 |
| Breo Ellipta | 17 | $9,229 | $543 |
| Combivent Respimat | 18 | $8,811 | $489 |
| Symbicort | 20 | $7,648 | $382 |
| Incruse Ellipta | 15 | $5,835 | $389 |
| Advair Diskus | 13 | $5,825 | $448 |
| Ethambutol | 35 | $2,535 | $72 |
| Azithromycin | 56 | $2,090 | $37 |
| Rifampin | 18 | $1,675 | $93 |
| Albuterol Sulfate Hfa | 58 | $1,467 | $25 |
| Montelukast | 25 | $402 | $16 |
| Prednisone | 26 | $123 | $5 |
2022: 8 drugs
| Trelegy Ellipta | 52 | $43,729 | $841 |
| Combivent Respimat | 27 | $12,788 | $474 |
| Breztri Aerosphere | 15 | $9,512 | $634 |
| Breo Ellipta | 19 | $8,053 | $424 |
| Incruse Ellipta | 19 | $7,005 | $369 |
| Albuterol Sulfate Hfa | 42 | $2,001 | $48 |
| Azithromycin | 16 | $429 | $27 |
| Prednisone | 17 | $138 | $8 |
2021: 5 drugs
| Dupixent | 11 | $37,644 | $3,422 |
| Trelegy Ellipta | 35 | $33,942 | $970 |
| Incruse Ellipta | 22 | $8,288 | $377 |
| Albuterol Sulfate Hfa | 27 | $1,440 | $53 |
| Prednisone | 12 | $49 | $4 |
2020: 4 drugs
| Trelegy Ellipta | 17 | $9,784 | $576 |
| Albuterol Sulfate Hfa | 11 | $721 | $66 |
| Ethambutol | 12 | $361 | $30 |
| Azithromycin | 13 | $203 | $16 |
2018: 1 drug
| Montelukast | 16 | $197 | $12 |
2017: 9 drugs
| Symbicort | 30 | $9,697 | $323 |
| Breo Ellipta | 23 | $9,389 | $408 |
| Advair Diskus | 13 | $5,807 | $447 |
| Flovent Hfa | 13 | $5,281 | $406 |
| Montelukast | 45 | $599 | $13 |
| Fluticasone Propionate | 31 | $457 | $15 |
| Prednisone | 35 | $457 | $13 |
| Azelastine | 11 | $432 | $39 |
| Omeprazole | 20 | $136 | $7 |
2013: 12 drugs
| Atrovent Hfa | 12 | $2,893 | $241 |
| Atorvastatin | 18 | $321 | $18 |
| Lisinopril | 27 | $220 | $8 |
| Gabapentin | 13 | $169 | $13 |
| Carvedilol | 15 | $130 | $9 |
| Losartan | 13 | $121 | $9 |
| Metoprolol | 18 | $121 | $7 |
| Levothyroxine | 13 | $113 | $9 |
| Baclofen | 12 | $101 | $8 |
| Prednisone | 14 | $66 | $5 |
| Simvastatin | 12 | $58 | $5 |
| Atenolol | 12 | $22 | $2 |
Money from drug and device companies
$1,080 in 2025
| 2025 | 6 | 23 | None | $1,080 |
| 2024 | 5 | 40 | None | $988 |
| 2023 | 4 | 28 | None | $800 |
| 2022 | 2 | 10 | None | $164 |
| 2021 | 2 | 2 | None | $28 |
| 2020 | 1 | 2 | None | $40 |
| 2019 | 2 | 4 | None | $223 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $462 | 7 payments
|
| Insmed | Arikayce | $350 | 9 payments
|
| Verona Pharma | Ohtuvayre | $111 | 3 payments
|
| Sanofi-Aventis U.S. | Dupixent | $100 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $42 | 2 payments
|
| GlaxoSmithKline | Nucala | $16 | 1 payment
|
See all 23 published payments
| Insmed | Meals · 2025-12-05 | Arikayce | $31 |
| Genzyme | Meals · 2025-12-03 | Dupixent | $36 |
| Insmed | Meals · 2025-11-30 | Arikayce | $7 |
| Insmed | Meals · 2025-11-05 | Arikayce | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-07 | Tezspire | $15 |
| Genzyme | Meals · 2025-09-11 | Dupixent | $90 |
| Genzyme | Meals · 2025-09-04 | Dupixent | $24 |
| Insmed | Meals · 2025-08-29 | Arikayce | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-26 | Fasenra | $27 |
| Verona Pharma | Meals · 2025-07-21 | Ohtuvayre | $27 |
| Insmed | Meals · 2025-06-18 | Arikayce | $35 |
| Insmed | Meals · 2025-05-14 | Arikayce | $30 |
| Insmed | Meals · 2025-05-07 | Arikayce | $134 |
| Insmed | Meals · 2025-04-04 | Arikayce | $22 |
| Genzyme | Meals · 2025-04-02 | Dupixent | $39 |
| Sanofi-Aventis U.S. | Education · 2025-04-02 | Dupixent | $100 |
| GlaxoSmithKline | Meals · 2025-04-01 | Nucala | $16 |
| Genzyme | Meals · 2025-03-07 | Dupixent | $40 |
| Genzyme | Meals · 2025-03-06 | Dupixent | $106 |
| Genzyme | Meals · 2025-02-05 | Dupixent | $126 |
| Insmed | Meals · 2025-01-29 | Arikayce | $28 |
| Verona Pharma | Meals · 2025-01-29 | Ohtuvayre | $52 |
| Verona Pharma | Meals · 2025-01-28 | Ohtuvayre | $32 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $988
| Insmed | Arikayce | $420 | 13 payments
|
| GlaxoSmithKline | Nucala | $188 | 20 payments
|
| Genzyme | Dupixent | $161 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $117 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $102 | 3 payments
|
2023: $800
| Genzyme | Dupixent | $365 | 4 payments
|
| GlaxoSmithKline | Arexvy | $221 | 13 payments
|
| Insmed | Arikayce | $189 | 10 payments
|
| Merck Sharp & Dohme | None | $24 | 1 payment
|
2022: $164
| Insmed | Arikayce | $151 | 9 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $14 | 1 payment
|
2021: $28
| GlaxoSmithKline | Trelegy Ellipta | $16 | 1 payment
|
| Insmed | Arikayce | $12 | 1 payment
|
2020: $40
| GlaxoSmithKline | Nucala | $40 | 2 payments
|
2019: $223
| Insmed | Arikayce | $192 | 2 payments
|
| Allergan | Avycaz | $31 | 2 payments
|
Professional record
- NPI
- 1699087833
- Licence
- CA A125591California A125591: Current · expires 2027-05-31
- Group
- Queens University Medical Group · The Queens Medical Center · Queens North Hawaii Community Hospital
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2010-07-03
- NPI last updated
- 2016-06-21
This is when the NPI record was last certified, not a medical board exam.